iMac Holdings Inc. Successfully Completes Third Cohort of Phase 1 Clinical Study for Parkinson’s Disease Treatment Using Umbilical Cord-Derived Mesenchymal Stem Cells
IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for Parkinson’s Disease BRENTWOOD, Tenn., Sept. 09, 2022 (GLOBE NEWSWIRE) — IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or “the Company”), today announces it has completed the third cohort of its Phase 1 clinical trial…